During outpatient follow-up, she was found to have high antinuclear antibody (ANA) titers as well as low complements, indicating the possibility of an underlying autoimmune disorder. This case underscores the need for concurrent antimalarial and immunosuppressive therapy in co-occurring autoimmune hemolytic anemia (AIHA)/malaria, with close monitoring for SLE progression given high ANA titers. The gene discussed is BTG3; the disease is autoimmune hemolytic anemia.